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Background/aim: Clinically isolated syndrome (CIS) may be the first presentation of pediatric onset multiple sclerosis (POMS). We
retrospectively evaluated the clinical and laboratory data of pediatric CIS (pCIS) patients who were diagnosed with POMS upon followup for any predictive variables. We also reviewed the literature concerning the management of pCIS.
Materials and methods: This single-center study involved patients who had pCIS in childhood that converted to POMS during followup between 2011 and 2021. Sixteen patients were included in the study. The data were evaluated retrospectively and analyzed with
descriptive statistics.
Results: The majority of the pCIS patients were female (F/M: 10/6, 62/38%), and the first pCIS attack was at 13.3 ± 2.6 years old (mean ±
SD). Mean follow-up was 3.1 ± 1.4 years; 6 of the patients relapsed within 1 year and 6 within 2 years. The time from the first pCIS attacks
of the patients to the diagnosis of POMS was 15.75 ± 11.07 months. The annualized relapse rate (ARR) was 0.9 ± 0.7. The majority (68%)
of the patients had a monosymptomatic onset, optic neuritis (ON) being the most common initial presentation (44%). Cerebrospinal
fluid (CSF) oligoclonal bands (OCBs) were found in 9/12 (75%) and the immunoglobulin G index (IgG index) was elevated in 5/11
(45%). An autoimmune disorder was reported in the 1st or 2nd degree relatives of 6 patients: four (25%) MS, one ulcerative colitis, and
one Hashimoto’s thyroiditis. Our pCIS patients did not receive any disease-modifying treatment (DMT) for their first attack. When the
diagnosis changed to POMS, most (68%) were started on interferons. The Expanded Disability Status Scale (EDSS) increased in one
patient during follow-up (EDSS: 3) while in the others it was 0 at the last visit. The literature is reviewed in order to compare results for
suggestions regarding the management of pCIS.
Conclusion: The presence of OCBs in the initial episode, MS in the family, and monosymptomatic onset may increase the possibility
of developing POMS. Whether DMTs given at the pCIS stage are effective in preventing relapses and disability needs to be evaluated in
longitudinal follow-up of large cohorts.
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I. Introduction
Multiple sclerosis (MS) is an inflammatory demyelinating
and eventually degenerative disease of the central nervous
system (CNS). Pediatric onset multiple sclerosis (POMS)
is defined as a disease whose first clinical episodes or
symptoms start before 18 years old, and it represents
3%–10% of the total MS cases [1–5]. POMS patients tend
to have higher relapse rates [6, 7], higher lesion loads
on magnetic resonance imaging (MRI) [8], and more
prominent cognitive deficits [9, 10]. The earlier onset and
more active course in POMS compared to adult MS may be
counterbalanced to some extent by the higher plasticity and
regeneration capacity in young individuals [4, 7, 11–15].

The initial demyelinating attack in POMS may present
as pediatric clinically isolated syndrome (pCIS) defined as
an acute or subacute, clinically monofocal or multifocal
CNS event of presumed inflammatory demyelinating
nature lasting at least 24 h. Encephalopathy should be
absent unless explained by fever or systemic illness, and no
past history of CNS demyelinating disease [optic neuritis
(ON), transverse myelitis (TM), hemispheric or brainstem related syndrome] should be reported. The lesions on
MRI should not show dissemination in time (DIT) or space
(DIS) [16–18]. The diagnostic criteria of the International
Pediatric Multiple Sclerosis Study Group (IPMSSG), more
suitable for children ≥12 years old, include the presence
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of cerebrospinal fluid (CSF) oligoclonal bands (OCBs)
as evidence for DIT. This facilitates the diagnosis and
increases the rate of POMS, concurrently reducing the
pCIS group [19].
The treatment of choice during the acute period in
pCIS is intravenous methylprednisolone (IVMP) [20]
as in other acquired demyelinating syndromes (ADSs),
and decisions about long-term treatment differ between
centers, being less clear than for adult CIS [20, 21].
Although there is no consensus on maintenance therapy
for pCIS, most specialists tend not to start treatment.
Predictive factors for the conversion of pCIS to MS
vary between studies and include ON in the first attack,
multiple well-defined periventricular or subcortical lesions
on MRI, presence of CSF OCBs, disability after the first
attack, a short interval between the first two demyelinating
episodes, a number of relapses, and progressive onset.
In a retrospective report on first ADS in childhood, the
presence of OCBs, past infection with Epstein–Barr virus
(EBV), periventricular lesions, hypointense lesions on
T1, and lesions of the corpus callosum including Dawson
fingers were described as predictive [22]. The lower
risk of conversion to MS in pCIS cases with negative
EBV serology has been supported by others [23]. No
consistent correlation was found with sex, age at onset,
polysymptomatic vs. monosymptomatic onset, or disease
course. In the present study, we aimed to retrospectively
evaluate the clinical and laboratory data of patients who
were diagnosed with pCIS that then evolved to POMS. We
also examined the predictive factors for pCIS progressing
to POMS by reviewing the literature.
II.Materials and methods
Patients who were diagnosed with pCIS at their first
ADS episode before 18 years old and diagnosed with
POMS during follow-up between July 2011 and July 2021
were included in the study. The diagnoses of pCIS and
POMS were made in accordance with the diagnostic
criteria of the IPMSSG [17], emphasizing the absence
of any previous attacks and the initial presentation not
meeting the diagnostic criteria for POMS. The clinical
and laboratory data of the patients were evaluated
retrospectively using the hospital database. With the
patients being under regular follow-up in the clinic,
consent could be obtained from the patient and/or the
parent for the use of their data for retrospective research.
The study was approved by Hacettepe University Ethics
Committee (Project number: GO 21/915 Decision
number 2021/14-77).
The statistical analyses were performed using a software
package (SPSS, IBM SPSS Statistics 24). The data were
classified using various parameters. Frequency tables and
descriptive statistics were used to interpret the findings.
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The literature search was conducted by entering the
words “pediatric, multiple sclerosis, clinically isolated
syndrome” into search engines such as PubMed, Google
Scholar, Embase, and the Cochrane database.
III. Results
Sixteen patients, 10 female (62%) and 6 male (38%), were
included in the study. Age at diagnosis of pCIS was 13.3 ±
2.6 (range 8.2–17.3, median: 13.4) years, age at diagnosis
of POMS was 14.6 ± 2.4 (range 9–18, median: 14.2) years,
and age at the time of the study was 16.3 ± 2.4 (range
10–19, median: 16.3) years. The time from the first pCIS
attacks to the diagnosis of POMS was 15.75 ± 11.07
(range: 2–48, median: 12) months. During follow-up, 9
patients (57%) had a second attack and were diagnosed
with POMS. Seven others (43%) who had no further
clinical attack fulfilled the MRI criteria due to increasing
lesion load on MRI. Therefore, all patients had a 2nd
demyelinating attack during mean 3.1±1.4 years’ (range
1–6) follow-up: six patients relapsed in the first year and
six others in the second year of follow-up. The annualized
relapse rate (ARR) of these 16 patients was 0.9 ± 0.7
(range 0.3–3 median 0.6) during this period.
Eleven patients’ (68%) first episode was
monosymptomatic (ON = 5, brainstem = 3, motor = 3) and
that of 5 patients (32%) was polysymptomatic (brainstemcerebellum = 3, brainstem-motor = 1, motor and sensory
= 1). A history of autoimmune disease was determined in
the 1st or 2nd degree relatives of 6 patients: four (25%)
MS, one ulcerative colitis, and one Hashimoto’s thyroiditis.
CSF was obtained in 12/16 pCIS patients, for diagnostic
purposes during the 1st (n = 4) or 2nd (n = 4) clinical
episode, or in the absence of any clinical event (n = 4).
Protein and cell counts were normal. OCBs were present
in 9/12 (75%) and IgG index was elevated in 5/11 (45%) of
the patients tested.
No disease-modifying treatments (DMTs) were given
until the establishment of the diagnosis of POMS. Patients
who met the diagnostic criteria with a new clinical attack
or radiological progression were diagnosed with POMS
and DMT was started: 11 (68%) with interferon (IFN),
4 (25%) with teriflunomide, and 1 (7%) with dimethyl
fumarate. Three patients showing increased disease
activity after receiving IFN had their treatment switched to
fingolimod, teriflunomide, or dimethyl fumarate. During
the last examination, the Expanded Disability Status Scale
(EDSS) scores were 0 in all patients except one, who had a
score of 3. Neuropsychiatric testing was not conducted in
any patients. All data are summarized in Table.
IV. Discussion
Our study shows that the majority of patients with pCIS that
evolved to POMS afterwards are postpubertal and female
and experience about one relapse per year on average.
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Table. Clinical data of pediatric clinically isolated syndrome patients.
Cohort n = 16

10F (62%) / 6M (38%)

Age at pCIS

13.3 ± 2.6 years (range 8.2–17.3, median: 13.4)

Age at POMS

14.6 ± 2.4 (range 9–18, median: 14.2)

Current age

16.3 ± 2.4 (range 10–19, median: 16.3)

ARR

0.9 ± 0.7 (range 0.3–3 median 0.6)

Symptomatology

Monosymptomatic n = 11 (68%). ON = 5 (44%), brainstem = 3 (28%), motor = 3 (28%)
Polysymptomatic n = 5 (32%). Brainstem-cerebellum = 3 (60%), brainstem-motor = 1 (20%),
motor and sensory = 1 (20%)

First DMTs

IFN-β = 11 (68%), teriflunomide = 4 (25%), dimethyl fumarate = 1 (7%)

Treatment switch

IFN-β to Fingolimod, Dimethyl fumarate, Teriflunomide, one each

OCB n = 12

9/12 positive (75%)

IgG index n = 11

5/11 had elevation (45%)

EDSS score

3 (n = 1), 0 (n = 15)

F: Female, M: Male, pCIS: Pediatric Clinically Isolated Syndrome, POMS: Pediatric Onset Multiple Sclerosis, ARR: Annualized Relapsing
Rate, ON: Optic Neuritis, DMT: Disease Modifying Treatment, IFN-β: Interferon Beta, OCB: Oligoclonal band, IgG: Immunoglobulin,
EDSS: Expanded Disability Status Scale.

They present monosymptomatically, frequently with ON
during the first clinical attack. Autoimmune diseases
can be detected in close family members. OCB presence
(75%) was more frequent than IgG index elevation (45%)
in patients with pCIS evolving to POMS. Disability is rare
in the first years. Among ADSs in children, pCIS was the
third most common after MS and acute disseminated
encephalomyelitis (ADEM) [24]. As in our study, the
most common presentation in pCIS is ON in the literature
(70%) and the diagnoses may change to ADEM (36%),
CIS (24%), MS (19%), or neuromyelitis optica spectrum
disorder (NMOSD) (7%) after 28 months’ follow-up [25].
In a multicenter retrospective study on POMS
comparing pre-/postpubertal onset, there was female
dominance and MS in relatives was found in 6.5% [26].
The distributions of sex and age were similar in our study,
but the rate of MS in relatives was higher. This variable is
to be compared between larger groups of CIS and POMS.
The presence of OCBs in CSF has been associated with
high lesion burden on MRI [27], and OCB positivity in
CIS cases may have a predictive role [28]. In our pCIS
series OCB positivity was 75%. The lumbar puncture was
done either at or after the second ADS; only four patients
underwent CSF analyses at the initial attack, of which
three were positive for OCBs. This finding did not lead to
a diagnosis of POMS in these patients because two were
before 2017 when OCBs were accepted as marker of DIT
and the other did not meet the DIS criteria [19, 29].
The clinical presentation of CIS can be monofocal or
multifocal. Derle et al. found onset of monosymptomatic

and brainstem/cerebellar nature was common in POMS
[30]. Certain studies showed that the presence of
brainstem/cerebellar symptoms and ON in the first attack
may have a predictive role in the diagnosis of POMS [28,
31, 32]. In our study, brainstem/cerebellar symptoms were
more frequent in polysymptomatic pCIS attacks and ON
was more frequent in monosymptomatic pCIS attacks. The
POMS series from Turkey shows the most common initial
clinical presentation was brainstem/cerebellar findings in
POMS, with polyfocal onset slightly higher than monofocal
(55.4 vs. 44.6%) [26]. According to our results, the first
clinical findings of pCIS tend to be monosymptomatic and
in the form of ON. More symptoms and signs are expected
to develop during the POMS period as the disease is more
disseminated compared to pCIS. On the other hand,
polysymptomatic CIS might be more prone to evolve into
MS; therefore, it would be worthwhile to prospectively
follow-up mono- and polysymptomatic ADS cases and
compare the rate of developing into POMS.
The following predictive parameters in the conversion
of CIS to MS have been studied extensively in adult
patients: nonwhite race, female sex, young age, disability
after attack, cerebellar syndrome, sphincter dysfunction,
cognitive impairment, fatigue, presence of CSF OCBs
or serum EBV IgG, MRI lesion load and localization,
contrast-enhancing lesions and black holes on MRI, retinal
axonal loss, smoking, and decreased vitamin D3 levels
[20, 33–37]. In recent years, neurofilament light chain
has been reported to be a valuable biomarker predicting
progression from CIS to MS in both pediatric and adult

1283

SOLMAZ and ÖNCEL / Turk J Med Sci
studies [38–40].
In recent years, the initiation of DMT in CIS tends to
be favored because of reports on EDSS remaining stable
under treatment. The rate of CIS converting to MS can be
as high as 85% in adults [41] and interferon, glatiramer
acetate, teriflunomide, and cladribine might have a
beneficial effect on conversion rates to MS [20]. Although
not directly on the maintenance treatment regimen in
pCIS, certain large-participant DMT studies included
pCIS cases [42]; confirmation by direct clinical trials in
pCIS is needed [43, 44]. Over 2.2–7.6 years’ follow-up,
the probability of pCIS turning into clinically definite
POMS can vary between 15% and 62% [45–50]. However,
no DMT regimen is approved by health authorities for
preventing pCIS developing into POMS [51, 52]. In the
absence of evidence-based data and guidelines on longterm treatment in pCIS, opinions and practice vary on this
issue [53].
Cognition is another function to be monitored in
POMS. Processing speed can be impaired in 23.4% of
POMS patients and in 16.4% of pCIS patients [54]. If
DMTs are shown to prevent cognitive impairment when
started at the stage of pCIS, early prescription of DMT may
be justified [54, 55]. For this reason, baseline assessment
and follow-up of cognitive functions are recommended in
POMS, with early initiation of DMT whenever cognition
appears affected, especially in patients with pCIS with a
high risk of converting into POMS. According to the
National Multiple Sclerosis Society recommendations,
although there is no definite consensus regarding the
advantages or disadvantages of using DMT for cognitive
impairment, in long-term follow-up all of the approved
DMTs have been shown to reduce the number and
severity of MS attacks and attenuate the signs of brain
damage seen on MRI, they may have beneficial effects on
cognitive function. 1Cognitive impairment is not listed as
an indication for starting DMT in POMS in many health
insurance systems. This issue needs to be addressed by
health authorities.
The largest studies of pCIS are of multicenter,
retrospective nature; follow-up of 770 pCIS patients for
at least 10 years revealed significantly higher incidence
of worsening EDSS in patients with initially multifocal,

isolated spinal cord, or ON attacks in comparison to those
with an initial supratentorial or brainstem syndrome.
Early DMT exposure prevented the second attack and
worsening of disability. Authors described these as novel
findings clearly demonstrating the importance of early
treatment in pCIS and POMS [56] as already reported for
adult CIS [57, 58]. Another retrospective observational
study confirmed abnormal cranial MRI, presence of OCB,
and age as independent predictors of conversion to POMS
in a series of children with isolated ON [59]. In our study,
OCB positivity, ON at monofocal onset, and brainstem or
cerebellar system involvement in polyfocal onset appeared
to have a predictive role in the transition from pCIS to
POMS, and the fact that the patients were on DMT in
the early phase of POMS may have prevented worsening
of their EDSS. The role of DMT, especially newer DMTs,
in preventing disease activity in pCIS has been suggested
[42]. However, healthcare regulations vary in different
countries and insurance coverage is an important factor
directing the treatment of POMS and particularly pCIS
[60].
Although our study is limited by its retrospective
nature, the small size of the series, the relatively short
follow-up period, the lack of neuropsychiatric tests to
evaluate cognitive status, and the absence of detailed
MRI and laboratory analyses, it allows a look at the early
stages of pCIS evolving into POMS, suggesting that OCB
positivity, family history, monosymptomatic presentation,
and ON are associated with POMS, and will serve as a basis
for further studies of natural course and management.
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